Roche to Invest up to $1.2B in Foundation Medicine, Take Majority Stake | GenomeWeb

NEW YORK (GenomeWeb) – Roche plans to take a majority stake worth more than $1 billion in oncology genomic testing firm Foundation Medicine, and will invest potentially more than $150 million in R&D, the companies said today. In addition, Roche will help to expand sales of Foundation's tests outside the US.

Roche will commence a tender offer for approximately 15.6 million shares of Foundation Medicine at $50 per share, for an aggregate value of about $780 million. The offer price is a 109 percent premium over Foundation Medicine's closing price last Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.